Cardiff Lexington (CDIX) Q2 2026 earnings summary

Executive summary

• Nova Ortho and Spine expanded to 12 locations across Florida and Georgia, including new sites in Tallahassee and Stuart, targeting high-demand, underserved markets and the 55+ demographic.

• Continued to add leading medical professionals and strengthen operational capabilities.

• Focused on long-term strategy to provide best-in-class care, fulfill critical healthcare needs, and drive shareholder value.

• Faced revenue decline due to fewer billed surgical procedures and lower realization rates on claim settlements.

Financial highlights

• Q2 2026 revenue was $2.16M, down from $2.79M in Q2 2025; YTD revenue was $4.38M, down from $5.70M YTD 2025.

• Gross profit margin for Q2 2026 was 54.7% (vs. 60.8% Q2 2025); YTD gross margin was 57%.

• Q2 2026 net loss was $2.48M, compared to $1.23M in Q2 2025; YTD net loss was $5.57M, compared to $1.68M YTD 2025.

• Adjusted EBITDA for Q2 2026 was $(177K), down from $708K in Q2 2025; YTD Adjusted EBITDA was $(14K), down from $1.25M YTD 2025.

• Interest expense rose to $2.1M from $1.9M year-over-year.

Outlook and guidance

• Patient volume is increasing, and management is focused on debt restructuring, working capital improvements, and returning to historical performance levels.

• Strategic investments and upgrading to OTCQX are planned to enhance access to working capital and support growth and M&A activity.

• Confident in the business model's ability to deliver consistent revenue growth and high returns on invested capital.